There are a range of possible treatments for Glaucoma, depending on the severity of disease progression. Treatments aim to reduce eye pressure by aiding fluid to drain from the eye. Physicians decide which treatment is best for a patient’s individual condition.
Traditional treatment options to delay glaucoma progression have significant limitations:
As a result, traditional treatment options may involve costly ongoing management and/or re-interventions.
New Minimally-Invasive Bleb Surgery (MIBS) devices can have fewer complications than traditional invasive surgery, but may still require significant follow-ups to manage the bleb.
MIGS devices are widely considered the future of glaucoma treatment. 5
LEARN MORE ABOUT MINIJECT
The MINIject® supraciliary MIGS addresses the limitations of traditional treatment by offering a minimally-invasive option that is safe, highly-effective and is sustained over time. 6
MINIject® is only available for sale in the European Union, the UK and Switzerland.
1 Ferreras A, Figus M, Fogagnolo P, Iester M, Frezzotti P. Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops. Curr Med Chem. 2019;26(22):4223-4224.
2 Rees G, Leong O, Crowston JG, Lamoureux EL. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. 2010 May;117(5):903-8.
3 Chi SC, Kang YN, Hwang DK, Liu CJ. Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. Br J Ophthalmol. 2020 Nov;104(11):1500-1507.
4 Baker ND, Barnebey HS, Moster MR, Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma. Ophthalmology 2021;128:1710-1721; Grover DS, Flynn WJ, Bashford KP. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. Am J Ophthalmol 2017;183:25–36
5 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021
6 Denis P, Hirneiß C, Durr GM, et al. “Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial”. Br J Ophthalmol 2020;0:1–6